{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:15:10Z","timestamp":1788524110810,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chronic kidney disease (CKD) affects approximately 10% of the global population, with limited therapeutic options to slow progression in moderate stages. The gut-kidney axis contributes to CKD progression, and probiotics are being investigated as potential therapeutic modulators. This double-blind, randomized, placebo-controlled trial investigated the effect of probiotic supplementation on CKD progression. Seventy-two patients with CKD stages 3 or 4 received either\n                    <jats:italic>Lactobacillus plantarum<\/jats:italic>\n                    (10\n                    <jats:sup>1<\/jats:sup>\n                    \u2070 CFU daily) or placebo for six months. The primary outcome was the change in estimated glomerular filtration rate (eGFR). The probiotic group demonstrated a significant increase in eGFR in contrast to a significant decline in the same variable in the placebo group. Treatment assignment was the sole independent predictor of eGFR change, with benefits observed across CKD stages 3 and 4, and in both diabetic and non-diabetic patients. Urinary indoxyl sulfate levels did not significantly differ between groups, and no correlation was found between its changes and eGFR improvement. No probiotic participants experienced CKD progression, compared to 8.6% in the placebo group. These findings suggest that\n                    <jats:italic>Lactobacillus plantarum<\/jats:italic>\n                    supplementation significantly ameliorates eGFR in patients with moderate to severe CKD through mechanisms independent of indoxyl sulfate reduction.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Trial Registration<\/jats:italic>\n                    : This trial was registered with ClinicalTrials.gov (Registration Number: NCT06863194) Registration date: 13 May 2025.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-67044-5","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:12:41Z","timestamp":1788520361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of probiotic supplementation on disease progression in patients with moderate to severe chronic kidney disease: a randomized controlled trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6578-3245","authenticated-orcid":false,"given":"Samar Elshahat","family":"Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherouk Salah Eldin","family":"Elnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ashraf","family":"Fouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagy","family":"Sayed-Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"10523","key":"67044_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0140-6736(25)01942-7","volume":"407","author":"WG Herrington","year":"2026","unstructured":"Herrington, W. G. et al. Chronic kidney disease. Lancet 407(10523), 90\u2013104 (2026).","journal-title":"Lancet"},{"key":"67044_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.biochi.2025.10.008","volume":"240","author":"C Braga","year":"2026","unstructured":"Braga, C. et al. Premature aging in chronic kidney disease: Decoding senescence biomarkers and therapeutic opportunities. Biochimie 240, 42\u201358 (2026).","journal-title":"Biochimie"},{"key":"67044_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1661037","volume":"16","author":"H Jiang","year":"2025","unstructured":"Jiang, H. et al. Gut microbiota dysbiosis in diabetic nephropathy: Mechanisms and therapeutic targeting via the gut-kidney axis. Front Endocrinol (Lausanne) 16, 1661037 (2025).","journal-title":"Front Endocrinol (Lausanne)"},{"key":"67044_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262110706","author":"IL Suliman","year":"2025","unstructured":"Suliman, I. L. et al. Gut microbiome in patients with chronic kidney disease stages 4 and 5: A systematic literature review. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms262110706 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"67044_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1535356","volume":"16","author":"J Zhu","year":"2025","unstructured":"Zhu, J. et al. The influence of gut microbiota on the gut-brain-kidney axis and its implications for chronic kidney disease. Front. Microbiol. 16, 1535356 (2025).","journal-title":"Front. Microbiol."},{"key":"67044_CR6","doi-asserted-by":"publisher","first-page":"1675458","DOI":"10.3389\/fmed.2025.1675458","volume":"12","author":"S Alobaidi","year":"2025","unstructured":"Alobaidi, S. The gut-kidney axis in chronic kidney disease: mechanisms, microbial metabolites, and microbiome-targeted therapeutics. Front Med. (Lausanne) 12, 1675458 (2025).","journal-title":"Front Med. (Lausanne)"},{"key":"67044_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178367","volume":"1008","author":"TK Wu","year":"2025","unstructured":"Wu, T. K. et al. Coral hydrate improves renal fibrosis by inhibiting indoxyl sulfate-induced ROS-mediated NLRP3 inflammasome activation. Eur. J. Pharmacol. 1008, 178367 (2025).","journal-title":"Eur. J. Pharmacol."},{"key":"67044_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10090367","author":"WC Liu","year":"2018","unstructured":"Liu, W. C., Tomino, Y. & Lu, K. C. Impacts of indoxyl sulfate and p-cresol sulfate on chronic kidney disease and mitigating effects of AST-120. Toxins (Basel) https:\/\/doi.org\/10.3390\/toxins10090367 (2018).","journal-title":"Toxins (Basel)"},{"issue":"2","key":"67044_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1053\/j.jrn.2022.07.008","volume":"33","author":"M Mitrovi\u0107","year":"2023","unstructured":"Mitrovi\u0107, M. et al. The impact of synbiotic treatment on the levels of gut-derived uremic toxins, inflammation, and gut microbiome of chronic kidney disease patients-A randomized trial. J. Ren. Nutr. 33(2), 278\u2013288 (2023).","journal-title":"J. Ren. Nutr."},{"issue":"8","key":"67044_CR10","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","volume":"11","author":"C Hill","year":"2014","unstructured":"Hill, C. et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11(8), 506\u2013514 (2014).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"67044_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1053\/j.jrn.2021.08.005","volume":"32","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Biotic supplements in patients with chronic kidney disease: Meta-analysis of randomized controlled trials. J. Ren. Nutr. 32(1), 10\u201321 (2022).","journal-title":"J. Ren. Nutr."},{"key":"67044_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/nu17071247","author":"R Cedillo-Flores","year":"2025","unstructured":"Cedillo-Flores, R. et al. Impact of gut microbiome modulation on uremic toxin reduction in chronic kidney disease: A systematic review and network meta-analysis. Nutrients https:\/\/doi.org\/10.3390\/nu17071247 (2025).","journal-title":"Nutrients"},{"issue":"2","key":"67044_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1590\/2175-8239-jbn-2022-0021en","volume":"45","author":"\u00c9MR de Ara\u00fajo","year":"2023","unstructured":"de Ara\u00fajo, \u00c9. M. R. et al. Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial. J. Bras Nefrol. 45(2), 152\u2013161 (2023).","journal-title":"J. Bras Nefrol."},{"key":"67044_CR14","doi-asserted-by":"publisher","first-page":"1434613","DOI":"10.3389\/fnut.2024.1434613","volume":"11","author":"C Liu","year":"2024","unstructured":"Liu, C. et al. Efficacy of probiotics\/synbiotics supplementation in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Front Nutr. 11, 1434613 (2024).","journal-title":"Front Nutr."},{"issue":"1","key":"67044_CR15","doi-asserted-by":"publisher","DOI":"10.5527\/wjn.v14.i1.101515","volume":"14","author":"D Chafekar","year":"2025","unstructured":"Chafekar, D. Optimizing chronic kidney disease management: The potential of a multi-strain probiotic formulation. World J. Nephrol. 14(1), 101515 (2025).","journal-title":"World J. Nephrol."},{"key":"67044_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.850014","volume":"9","author":"J Tan","year":"2022","unstructured":"Tan, J. et al. Effectiveness of microecological preparations for improving renal function and metabolic profiles in patients with chronic kidney disease. Front. Nutr. 9, 850014 (2022).","journal-title":"Front. Nutr."},{"issue":"10","key":"67044_CR17","volume":"10","author":"TE Cooper","year":"2023","unstructured":"Cooper, T. E. et al. Synbiotics, prebiotics and probiotics for people with chronic kidney disease. Cochrane Database Syst. Rev. 10(10), Cd013631 (2023).","journal-title":"Cochrane Database Syst. Rev."},{"key":"67044_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/toxins18010006","author":"T Obrero","year":"2025","unstructured":"Obrero, T. et al. Probiotic supplementation in chronic kidney disease: Outcomes on uremic toxins, inflammation, and vascular calcification from experimental and clinical models. Toxins (Basel) https:\/\/doi.org\/10.3390\/toxins18010006 (2025).","journal-title":"Toxins (Basel)"},{"issue":"5","key":"67044_CR19","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1159\/000494677","volume":"43","author":"L Jia","year":"2018","unstructured":"Jia, L. et al. Efficacy of probiotics supplementation on chronic kidney disease: A systematic review and meta-analysis. Kidney Blood Press. Res. 43(5), 1623\u20131635 (2018).","journal-title":"Kidney Blood Press. Res."},{"key":"67044_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodres.2026.118376","volume":"228","author":"Q Mo","year":"2026","unstructured":"Mo, Q. et al. Lactiplantibacillus pentosus JWN01 and Lactiplantibacillus plantarum JWN02 attenuate renal fibrosis and pathological autophagy in hyperuricemic nephropathy via gut-kidney axis. Food Res. Int. 228, 118376 (2026).","journal-title":"Food Res. Int."},{"key":"67044_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262010052","author":"H Kim","year":"2025","unstructured":"Kim, H. et al. Lactiplantibacillus plantarum HY7718 attenuates renal injury in an adenine-induced chronic kidney disease mouse model via inhibition of inflammation and apoptosis. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms262010052 (2025).","journal-title":"Int. J. Mol. Sci."},{"issue":"1\u20132","key":"67044_CR22","first-page":"1","volume":"72","author":"T Niwa","year":"2010","unstructured":"Niwa, T. Uremic toxicity of indoxyl sulfate. Nagoya J. Med. Sci. 72(1\u20132), 1\u201311 (2010).","journal-title":"Nagoya J. Med. Sci."},{"key":"67044_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12110684","author":"TH Cheng","year":"2020","unstructured":"Cheng, T. H. et al. Indoxyl sulfate, a tubular toxin, contributes to the development of chronic kidney disease. Toxins (Basel) https:\/\/doi.org\/10.3390\/toxins12110684 (2020).","journal-title":"Toxins (Basel)"},{"key":"67044_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27123848","author":"A Pieniazek","year":"2022","unstructured":"Pieniazek, A. et al. Indoxyl sulfate induces oxidative changes in plasma and hemolysate. Molecules https:\/\/doi.org\/10.3390\/molecules27123848 (2022).","journal-title":"Molecules"},{"issue":"4","key":"67044_CR25","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/labinvest.2011.194","volume":"92","author":"SH Kim","year":"2012","unstructured":"Kim, S. H. et al. Indoxyl sulfate-induced epithelial-to-mesenchymal transition and apoptosis of renal tubular cells as novel mechanisms of progression of renal disease. Lab. Invest. 92(4), 488\u2013498 (2012).","journal-title":"Lab. Invest."},{"key":"67044_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/toxins8120358","author":"SC Leong","year":"2016","unstructured":"Leong, S. C. & Sirich, T. L. Indoxyl sulfate-review of toxicity and therapeutic strategies. Toxins (Basel) https:\/\/doi.org\/10.3390\/toxins8120358 (2016).","journal-title":"Toxins (Basel)"},{"key":"67044_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1660226","volume":"16","author":"C Liu","year":"2025","unstructured":"Liu, C. et al. Gut microbiota therapy for chronic kidney disease. Front. Immunol. 16, 1660226 (2025).","journal-title":"Front. Immunol."},{"issue":"2","key":"67044_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2215\/CJN.05240515","volume":"11","author":"M Rossi","year":"2016","unstructured":"Rossi, M. et al. Synbiotics easing renal failure by improving gut microbiology (SYNERGY): A randomized trial. Clin. J. Am. Soc. Nephrol. 11(2), 223\u2013231 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"6","key":"67044_CR29","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s40620-020-00955-2","volume":"34","author":"K Takkavatakarn","year":"2021","unstructured":"Takkavatakarn, K. et al. Protein-bound uremic toxin lowering strategies in chronic kidney disease: A systematic review and meta-analysis. J. Nephrol. 34(6), 1805\u20131817 (2021).","journal-title":"J. Nephrol."},{"issue":"7","key":"67044_CR30","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1097\/01.ASN.0000022017.96399.B2","volume":"13","author":"A Enomoto","year":"2002","unstructured":"Enomoto, A. et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J. Am. Soc. Nephrol. 13(7), 1711\u20131720 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"67044_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.semnephrol.2014.02.010","volume":"34","author":"R Masereeuw","year":"2014","unstructured":"Masereeuw, R. et al. The kidney and uremic toxin removal: Glomerulus or tubule?. Semin. Nephrol. 34(2), 191\u2013208 (2014).","journal-title":"Semin. Nephrol."},{"issue":"3","key":"67044_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.jrn.2006.04.020","volume":"16","author":"K Taki","year":"2006","unstructured":"Taki, K. et al. Accumulation of indoxyl sulfate in OAT1\/3-positive tubular cells in kidneys of patients with chronic renal failure. J. Ren. Nutr. 16(3), 199\u2013203 (2006).","journal-title":"J. Ren. Nutr."},{"issue":"4","key":"67044_CR33","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s12602-024-10427-9","volume":"17","author":"FPB Ribeiro","year":"2025","unstructured":"Ribeiro, F. P. B. et al. Gut dysbiosis and probiotic therapy in chronic kidney disease: A comprehensive review. Probiotics Antimicrob. Proteins 17(4), 1797\u20131819 (2025).","journal-title":"Probiotics Antimicrob. Proteins"},{"key":"67044_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfag082","author":"W Zadora","year":"2026","unstructured":"Zadora, W. et al. Intestinal barrier dysfunction in chronic kidney disease: Evidence, mechanisms, and its potential clinical implications. Nephrol. Dial. Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfag082 (2026).","journal-title":"Nephrol. Dial. Transplant."},{"key":"67044_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/nu17172904","author":"M Szrejder","year":"2025","unstructured":"Szrejder, M. & Piwkowska, A. Gut microbiome-derived short-chain fatty acids in glomerular protection and modulation of chronic kidney disease progression. Nutrients https:\/\/doi.org\/10.3390\/nu17172904 (2025).","journal-title":"Nutrients"},{"key":"67044_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60111821","author":"E Longhitano","year":"2024","unstructured":"Longhitano, E. et al. Proteinuria and progression of renal damage: The main pathogenetic mechanisms and pharmacological approach. Medicina (Kaunas) https:\/\/doi.org\/10.3390\/medicina60111821 (2024).","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"67044_CR37","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.2215\/CJN.01670211","volume":"6","author":"MR Weir","year":"2011","unstructured":"Weir, M. R. et al. Hemodynamic correlates of proteinuria in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6(10), 2403\u20132410 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"67044_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13050334","author":"C Cosola","year":"2021","unstructured":"Cosola, C. et al. An innovative synbiotic formulation decreases free serum indoxyl sulfate, small intestine permeability and ameliorates gastrointestinal symptoms in a randomized pilot trial in stage IIIb-IV CKD patients. Toxins (Basel) https:\/\/doi.org\/10.3390\/toxins13050334 (2021).","journal-title":"Toxins (Basel)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-67044-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-67044-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-67044-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:30:53Z","timestamp":1788521453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-67044-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67044"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-67044-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"17 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the authors used ChatGPT (OpenAI) to assist with language editing and refinement. The tool was not used to design the study, analyze data, interpret results, or draw conclusions. All content was reviewed and verified by the authors, who take full responsibility for the final manuscript.","order":2,"name":"Ethics","label":"Use of AI and AI-assisted technologies","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27799"}}